Advertisement
Advertisement
Aytu BioPharma price target lowered to $7 from $9 at Maxim
PremiumThe FlyAytu BioPharma price target lowered to $7 from $9 at Maxim
2M ago
Aytu BioPharma Reports Fiscal 2025 Earnings and EXXUA Launch Plans
Premium
Company Announcements
Aytu BioPharma Reports Fiscal 2025 Earnings and EXXUA Launch Plans
2M ago
AYTU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AYTU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs
PremiumThe FlyAytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs
5M ago
Aytu BioScience Expands Lending Agreement for EXXUA Launch
Premium
Company Announcements
Aytu BioScience Expands Lending Agreement for EXXUA Launch
5M ago
Aytu BioPharma expands, extends lending agreement with Eclipse
Premium
The Fly
Aytu BioPharma expands, extends lending agreement with Eclipse
5M ago
Aytu BioPharma 9.6M share Secondary priced at $1.50
PremiumThe FlyAytu BioPharma 9.6M share Secondary priced at $1.50
5M ago
Aytu BioPharma enters exclusive agreement with Fabre-Kramer Pharmaceuticals
Premium
The Fly
Aytu BioPharma enters exclusive agreement with Fabre-Kramer Pharmaceuticals
5M ago
Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering
Premium
The Fly
Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100